Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180 BLS Pharmaceuticals Ltd | ASX:BLS | www.blspharma.com 1 15 October 2026 Quarterly Activities Report Period Ending 30 September 2026 Record $26.7 million Q1 revenue provides...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 11 pages · English
Summary by 6ix AI
The report indicates a strong start to the financial year, with significant growth in cash receipts and positive operating cash flow. The company reaffirms its revenue guidance for the financial year, projecting substantial growth compared to the previous year. BLS continues to expand its manufacturing capabilities both domestically and internationally, particularly in Germany and the United Kingdom.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
BLS Pharmaceuticals Limited on 6ix
Earlier from BLS Pharmaceuticals
- Ceasing to be a substantial holder
- Becoming a substantial holder
- AGM Date and Director Nominations
- Application for quotation of securities - BLS
- Initial Director's Interest Notice
Later from BLS Pharmaceuticals
- BLS Quarterly Activities Report September 2026 Revised
- Q1 FY2027 Quarterly Activities Update
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders re Annual General Meeting
- Directors Change of Interest Notice X 2
Follow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals